Innovent Biologics announces multiple mechanism-of-action analyses of mazdutide

Written by Emily J. Thompson, Senior Investment Analyst

Updated: Jun 22 2025

0mins

Innovent Biologics Presentations: Innovent Biologics will showcase multiple analyses of mazdutide and a preclinical study of IBI3030 at the ADA's 85th Scientific Sessions, focusing on their effects on cardiovascular risk markers and liver fat accumulation.
Mechanism of Action Insights: The presentations will highlight how mazdutide, a dual GLP-1R/GCGR agonist, alleviates conditions such as MASH, hepatic fibrosis, and hyperuricemia by modulating energy and lipid metabolism.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.